Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
40
SMTI Quote, Financials, Valuation and Earnings
Last price:
$24.60
Seasonality move
:
33.98%
Day range:
$24.46 - $24.85
52-week range:
$18.90 - $38.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.07x
P/B ratio:
35.63x
Volume:
18.7K
Avg. volume:
62.5K
1-year change:
-29.82%
Market cap:
$219.1M
Revenue:
$86.7M
EPS (TTM):
-$4.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$26.6M | -- | 5.59% | -- | $41.00 |
|
ATR
AptarGroup, Inc.
|
$951.9M | $1.57 | 3.79% | -16.85% | $161.43 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
DXR
Daxor Corp.
|
-- | -- | -- | -- | $22.00 |
|
POCI
Precision Optics Corp., Inc.
|
-- | -- | -- | -- | -- |
|
WRBY
Warby Parker, Inc.
|
$224.5M | $0.09 | 11.85% | -- | $26.33 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$24.52 | $41.00 | $219.1M | -- | $0.00 | 0% | 2.07x |
|
ATR
AptarGroup, Inc.
|
$122.78 | $161.43 | $8.1B | 19.68x | $0.48 | 1.49% | 2.26x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8150 | $12.3077 | $209.3M | -- | $0.00 | 0% | 190.87x |
|
DXR
Daxor Corp.
|
$13.82 | $22.00 | $68.9M | 37.90x | $0.00 | 0% | 64.09x |
|
POCI
Precision Optics Corp., Inc.
|
$4.10 | -- | $31.6M | -- | $0.00 | 0% | 1.36x |
|
WRBY
Warby Parker, Inc.
|
$26.33 | $26.33 | $3.2B | 6,928.95x | $0.00 | 0% | 3.82x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
88.52% | 0.759 | 16.72% | 1.64x |
|
ATR
AptarGroup, Inc.
|
31.09% | 0.203 | 14.19% | 0.73x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
DXR
Daxor Corp.
|
2% | 1.958 | -- | 0.09x |
|
POCI
Precision Optics Corp., Inc.
|
29.28% | 0.770 | 13.48% | 0.74x |
|
WRBY
Warby Parker, Inc.
|
38.62% | 3.047 | 6.9% | 2.13x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SMTI
Sanara MedTech, Inc.
|
$23.8M | $3M | -8.95% | -20.48% | 11.25% | $1.1M |
|
ATR
AptarGroup, Inc.
|
$287.9M | $139.1M | 11.15% | 15.97% | 14.47% | $114M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
DXR
Daxor Corp.
|
-- | -- | 1.52% | 1.57% | -- | -- |
|
POCI
Precision Optics Corp., Inc.
|
$946.4K | -$1.6M | -43.33% | -54.55% | -23.88% | -$226.6K |
|
WRBY
Warby Parker, Inc.
|
$115.6M | $3.6M | 0.13% | 0.2% | 1.62% | -$1.5M |
Sanara MedTech, Inc. vs. Competitors
-
Which has Higher Returns SMTI or ATR?
AptarGroup, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 13.3%. Sanara MedTech, Inc.'s return on equity of -20.48% beat AptarGroup, Inc.'s return on equity of 15.97%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M ATRAptarGroup, Inc.29.95% $1.92 $4.1B -
What do Analysts Say About SMTI or ATR?
Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 67.21%. On the other hand AptarGroup, Inc. has an analysts' consensus of $161.43 which suggests that it could grow by 32.11%. Given that Sanara MedTech, Inc. has higher upside potential than AptarGroup, Inc., analysts believe Sanara MedTech, Inc. is more attractive than AptarGroup, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 ATRAptarGroup, Inc.4 2 0 -
Is SMTI or ATR More Risky?
Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison AptarGroup, Inc. has a beta of 0.500, suggesting its less volatile than the S&P 500 by 49.958%.
-
Which is a Better Dividend Stock SMTI or ATR?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AptarGroup, Inc. offers a yield of 1.49% to investors and pays a quarterly dividend of $0.48 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. AptarGroup, Inc. pays out 31.12% of its earnings as a dividend. AptarGroup, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMTI or ATR?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than AptarGroup, Inc. quarterly revenues of $961.1M. Sanara MedTech, Inc.'s net income of $834.5K is lower than AptarGroup, Inc.'s net income of $127.8M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while AptarGroup, Inc.'s PE ratio is 19.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 2.07x versus 2.26x for AptarGroup, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.2.07x -- $26.3M $834.5K ATRAptarGroup, Inc.2.26x 19.68x $961.1M $127.8M
-
Which has Higher Returns SMTI or CATX?
Perspective Therapeutics, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of -12425.36%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About SMTI or CATX?
Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 67.21%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 349.19%. Given that Perspective Therapeutics, Inc. has higher upside potential than Sanara MedTech, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Sanara MedTech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is SMTI or CATX More Risky?
Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock SMTI or CATX?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or CATX?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Sanara MedTech, Inc.'s net income of $834.5K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 2.07x versus 190.87x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.2.07x -- $26.3M $834.5K CATXPerspective Therapeutics, Inc.190.87x -- $209K -$26M
-
Which has Higher Returns SMTI or DXR?
Daxor Corp. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of --. Sanara MedTech, Inc.'s return on equity of -20.48% beat Daxor Corp.'s return on equity of 1.57%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M DXRDaxor Corp.-- -- $36.5M -
What do Analysts Say About SMTI or DXR?
Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 67.21%. On the other hand Daxor Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 59.15%. Given that Sanara MedTech, Inc. has higher upside potential than Daxor Corp., analysts believe Sanara MedTech, Inc. is more attractive than Daxor Corp..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 DXRDaxor Corp.0 0 0 -
Is SMTI or DXR More Risky?
Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Daxor Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100.015%.
-
Which is a Better Dividend Stock SMTI or DXR?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daxor Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Daxor Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or DXR?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Daxor Corp. quarterly revenues of --. Sanara MedTech, Inc.'s net income of $834.5K is higher than Daxor Corp.'s net income of --. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Daxor Corp.'s PE ratio is 37.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 2.07x versus 64.09x for Daxor Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.2.07x -- $26.3M $834.5K DXRDaxor Corp.64.09x 37.90x -- --
-
Which has Higher Returns SMTI or POCI?
Precision Optics Corp., Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of -24.5%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Precision Optics Corp., Inc.'s return on equity of -54.55%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M POCIPrecision Optics Corp., Inc.14.17% -$0.21 $15.4M -
What do Analysts Say About SMTI or POCI?
Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 67.21%. On the other hand Precision Optics Corp., Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Sanara MedTech, Inc. has higher upside potential than Precision Optics Corp., Inc., analysts believe Sanara MedTech, Inc. is more attractive than Precision Optics Corp., Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 POCIPrecision Optics Corp., Inc.0 0 0 -
Is SMTI or POCI More Risky?
Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Precision Optics Corp., Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.404%.
-
Which is a Better Dividend Stock SMTI or POCI?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precision Optics Corp., Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Precision Optics Corp., Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or POCI?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are larger than Precision Optics Corp., Inc. quarterly revenues of $6.7M. Sanara MedTech, Inc.'s net income of $834.5K is higher than Precision Optics Corp., Inc.'s net income of -$1.6M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Precision Optics Corp., Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 2.07x versus 1.36x for Precision Optics Corp., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.2.07x -- $26.3M $834.5K POCIPrecision Optics Corp., Inc.1.36x -- $6.7M -$1.6M
-
Which has Higher Returns SMTI or WRBY?
Warby Parker, Inc. has a net margin of 3.17% compared to Sanara MedTech, Inc.'s net margin of 2.65%. Sanara MedTech, Inc.'s return on equity of -20.48% beat Warby Parker, Inc.'s return on equity of 0.2%.
Company Gross Margin Earnings Per Share Invested Capital SMTISanara MedTech, Inc.90.56% -$3.52 $53.5M WRBYWarby Parker, Inc.52.13% $0.05 $602.2M -
What do Analysts Say About SMTI or WRBY?
Sanara MedTech, Inc. has a consensus price target of $41.00, signalling upside risk potential of 67.21%. On the other hand Warby Parker, Inc. has an analysts' consensus of $26.33 which suggests that it could grow by 0.01%. Given that Sanara MedTech, Inc. has higher upside potential than Warby Parker, Inc., analysts believe Sanara MedTech, Inc. is more attractive than Warby Parker, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMTISanara MedTech, Inc.2 0 0 WRBYWarby Parker, Inc.7 4 0 -
Is SMTI or WRBY More Risky?
Sanara MedTech, Inc. has a beta of 1.182, which suggesting that the stock is 18.199% more volatile than S&P 500. In comparison Warby Parker, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SMTI or WRBY?
Sanara MedTech, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Warby Parker, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sanara MedTech, Inc. pays -- of its earnings as a dividend. Warby Parker, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SMTI or WRBY?
Sanara MedTech, Inc. quarterly revenues are $26.3M, which are smaller than Warby Parker, Inc. quarterly revenues of $221.7M. Sanara MedTech, Inc.'s net income of $834.5K is lower than Warby Parker, Inc.'s net income of $5.9M. Notably, Sanara MedTech, Inc.'s price-to-earnings ratio is -- while Warby Parker, Inc.'s PE ratio is 6,928.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sanara MedTech, Inc. is 2.07x versus 3.82x for Warby Parker, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMTISanara MedTech, Inc.2.07x -- $26.3M $834.5K WRBYWarby Parker, Inc.3.82x 6,928.95x $221.7M $5.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
